Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole, quetiapine, or risperidone
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
This entry refers to a group of second-generation (atypical) antipsychotics—aripiprazole, quetiapine, and risperidone—commonly used as standard-of-care treatments for pediatric psychiatric disorders, including schizophrenia, bipolar mania, and irritability associated with autism. These agents are characterized by their activity at dopamine D2 and serotonin 5-HT2A receptors, though they differ in their specific receptor binding profiles and side-effect risks, particularly regarding weight gain and metabolic changes. In the context of the Northwell Health clinical trial (NCT01397799), these three drugs constitute the 'Usual Care' (UC) arm, which is being compared against ziprasidone to evaluate differences in drug-induced weight gain, stratified by MC4R genotype.
- Brand names
- AbilifySeroquelRisperdal
- Other names
- aripiprazolequetiapinerisperidoneatypical antipsychoticssecond-generation antipsychotics
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on aripiprazole, quetiapine, or risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole, quetiapine, or risperidone.